UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2024
Commission File Number: 001-39461
NANO-X IMAGING LTD
Ofer Tech Park
94 Shlomo Shmeltzer Road
Petach Tikva
Israel 4970602
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
On August 20, 2024, NANO-X IMAGING LTD (the “Company”)
issued a press release, a copy of which is attached hereto as Exhibit 99.1, and incorporated herein by reference.
In the press release the Company uses certain
financial measures that are not prepared in accordance with generally accepted accounting principles in the United States (“GAAP”).
The non-GAAP financial measures that appear in the press release exclude among other things legal and other related expenses in relation
to the following legal matters.
For information on other components that were
excluded in preparation of the non-GAAP financial measures, please refer to the press release.
The GAAP financial statements tables contained
in the press release attached to this Report on Form 6-K are incorporated by reference the Company’s Registration Statement on Form F-3, File No. 333-271688, and Form S-8, File No. 333-248322.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
NANO-X IMAGING LTD |
| |
|
| |
By: |
/s/ Ran Daniel |
| |
Name: |
Ran Daniel |
| |
Title: |
Chief Financial Officer |
Date: August 20, 2024
Exhibit
99.1
Nanox
Announces Second Quarter of 2024 Financial Results and
Provides
Business Update
Accelerated
the deployment of Nanox ARC in the US market,
Submitted
a new 510k application to the FDA to expand Nanox.ARC indications to include
general
use, including chest
Nanox.AI Receives FDA
510K Clearance for HealthCCSng V 2.0, upgraded version of its AI Cardiac Solution
Management
to host conference call and webcast Tuesday, August 20, 2024 at 8:30 AM ET
PETAH
TIKVA, Israel— August 20, 2024 — NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”),
an innovative medical imaging technology company, today announced results for the second quarter ended June 30, 2024 and provided a business
update.
Recent
Highlights:
| ● | Generated
$2.7 million in revenue in the second quarter of 2024, compared to $2.6 million in the second
quarter of 2023. |
| ● | Submitted
a new 510k submission to the FDA to expand the intended use cases for the Nanox.ARC for general
use, including chest. |
| ● | Advanced
the US deployment program for the Nanox.ARC technology, with systems installed in seven states,
and a robust sales pipeline. |
| ● | Installed
initial Nanox.ARC systems as part of three chain medical imaging service providers in the
US. |
| ● | Announces
the development of system to be called Nanox.ARC X, that will be introduced in our next investor
relations’ event |
| | | |
| | ● | Nanox.AI Receives FDA 510K Clearance for HealthCCSng V2.0, upgraded version of the cardiac solution, introduces additional ‘zero
calcium’ categorization of coronary calcium (CAC) and generates an exact calcium score with corresponding CAC detection category
output. |
| | | |
| | ● | Nanox.AI Cardiac Solution, HealthCCSng, was highlighted in multiple scientific presentations at the 2024 SSCCT annual meeting. |
“The second quarter of 2024 was one of commercial
advances as the Nanox team pursues its vision of making medical imaging more accessible worldwide,” said Erez Meltzer, Nanox Chief
Executive Officer and Acting Chairman. “Our vision is to extend Nanox technology within and beyond hospitals, targeting underserved
segments like urgent care and orthopedic clinics. We deliver a seamless scan-to-diagnosis solution, leveraging AI for smarter, more efficient
healthcare, with a focus on aligning innovation with clinical needs to enhance patient outcomes globally. Nanox is dedicated to accelerating
the execution of our commercial infrastructure and future strategic collaborations in the U.S. Our mission is to provide healthcare practices
with a transformative imaging advantage with the Nanox.ARC – an accessible, cost-effective solution that not only provides advanced
diagnostic imaging capabilities but also elevates overall patient care”.
Financial
results for three months ended June 30, 2024
For
the three months ended June 30, 2024 (the “reported period”), the Company reported a net loss of $13.6 million, compared
to a net loss of $17.4 million for the three months ended June 30, 2023 (which is referred as the “comparable period”), representing
a decrease of $3.8 million. The decrease was largely due to a decrease of $2.1 million in the research and development expenses and a
decrease of $1.7 million in the general and administrative expenses and increase of $0.5 million in the Company’s financial income
which was mitigated by an increase of $1.2 in the Company’s gross loss.
The
Company reported revenue of $2.7 million in the reported period, compared to $2.6 million in the comparable period. During the reported
period, the Company generated revenue through teleradiology services, the sales of its Imaging devices and services and the sale of its
AI solutions.
The Company’s gross loss during the reported
period totaled $2.9 million (gross loss margin of 106%)) on a GAAP basis, as compared to $1.7 million (gross loss margin of (66%)) in
the comparable period. Non-GAAP gross loss for the reported period was $0.2 million (gross loss margin of approximately 9%), as compared
to Non-GAAP gross profit of $0.9 million (gross profit margin of approximately 34%) in the comparable period.
The Company’s revenue from teleradiology services
for the reported and comparable periods was $2.5 million. The Company’s GAAP gross profit from teleradiology services for the reported
and comparable periods was $0.4 million (gross profit margin of approximately 15%) a. Non-GAAP gross profit of the Company’s
teleradiology services for the reported and comparable periods was $0.9 million (gross profit margin of approximately 37%).
During
the reported period the Company generated revenue through the sales and deployment of its imaging systems which amounted to $68 thousand
for the reported period, with a gross loss of $1.3 million on a GAAP and non-GAAP basis. The revenue stems from the sale and deployment
of our 2D systems in Africa and our Nanox.ARC systems in the U.S.
The
Company’s revenue from its AI solutions for the reported period was $113 thousand with a gross loss of $2.0 million on a GAAP basis,
as compared to revenue of $53 thousand with a gross loss of $2.1 million in the comparable period. Non-GAAP gross profit of the Company’s
AI solutions for the reported period was $57 thousand, as compared to a loss of 42 thousand in the comparable period.
Research and development expenses, net for the reported
period were $4.8 million, as compared to $6.9 million in the comparable period, reflecting a decrease of $2.1 million. The decrease was
mainly due to decrease of $1.2 million in salaries and wages and a decrease of $0.2 million in share-based compensation and $0.7 million
in the expenses related to our research and development activities.
Sales
and marketing expenses for the reported and the comparable periods were $0.8 million.
General
and administrative expenses for the reported period were $5.9 million, as compared to $7.6 million in the comparable period. The decrease
of $1.7 million was mainly due to a decrease in our legal expenses in the amount of $1.6 million, largely as result of the finalization
of the SEC investigation and the settlement of the class action and a decrease in the cost of the directors’ and officers’
liability insurance premium in the amount of $0.4 million.
Non-GAAP
net loss attributable to ordinary shares for the reported period was $8.4 million, as compared to $9.9 million in the comparable period.
The decrease of $1.5 million was mainly due to a decrease in non-GAAP operating expenses of $2.2 million and an increase of $0.5 million
in our non-GAAP interest income which was offset by decrease of $1.1 million in our non-GAAP gross profit.
Non-GAAP
gross loss for the reported period was $0.2 million, as compared to a Non-GAAP gross profit of $0.9 million in the comparable period.
Non-GAAP research and development expenses, net for the reported period, were $4.1 million, as compared to $6.0 million in the comparable
period. Non-GAAP sales and marketing expenses for the reported period were $0.5 million, as compared to $0.6 million in the comparable
period. Non-GAAP general and administrative expenses for the reported period were $4.3 million as compared to $4.7 million in the comparable
period.
The
difference between the GAAP and non-GAAP financial measures above is mainly attributable to amortization of intangible assets, share-based
compensation, change in contingent earnout liability, expenses related to an offering and legal fee in connection with the class-action
litigation and the SEC investigation. A reconciliation between GAAP and non-GAAP financial measures for the three and six months periods
ended June 30, 2024, and 2023 is provided in the financial results that are part of this press release.
Liquidity
and Capital Resources
As
of Jume 30, 2024, the Company had total cash, cash equivalents, restricted deposits and marketable securities of $64.2 million, compared
to $82.8 million as of December 31, 2023. The decrease of $18.6 million during the reported period was primarily due to negative cash
flow from operations of $17.9 million.
Other
Assets
As
of June 30, 2024 the Company had property and equipment of $44.4 million, compared to $42.3 million as of December 31, 2023.
As
of June 30, 2024, the Company had intangible assets of $75.3 million as compared to $80.6 million as of December 31, 2023. The decrease
was attributable to the periodic amortization of intangible assets in the amount of $5.3 million.
Shareholders’
Equity
As
of June 30, 2024 the Company had approximately 58.5 million shares outstanding. As of December 31, 2023, the Company had approximately
57.8 million shares outstanding.
Conference
Call and Webcast Details
Tuesday,
August 20, 2024 @ 8:30am ET
Individuals
interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Nanox website under
Events and Presentations. Alternatively, individuals can register online to receive a dial-in number and personalized PIN to participate
in the call. An archived webcast of the event will be available for replay following the event.
About
Nanox:
Nanox
(NASDAQ: NNOX) is focused on applying its proprietary medical imaging technology and solutions to make diagnostic medicine more accessible
and affordable across the globe. Nanox’s vision is to increase access, reduce costs and enhance the efficiency of routine medical
imaging technology and processes, in order to improve early detection and treatment, which Nanox believes is key to helping people achieve
better health outcomes, and, ultimately, to save lives. The Nanox ecosystem includes Nanox.ARC— a multi-source Digital Tomosynthesis
system that is cost-effective and user-friendly; an AI-based suite of algorithms that augment the readings of routine CT imaging to highlight
early signs often related to chronic disease (Nanox.AI); a cloud-based infrastructure (Nanox.CLOUD); and a proprietary decentralized
marketplace, through Nanox’s subsidiary, USARAD Holdings Inc., that provides remote access to radiology and cardiology experts;
and a comprehensive teleradiology services platform (Nanox.MARKETPLACE). Together, Nanox’s products and services create a worldwide,
innovative, and comprehensive solution that connects medical imaging solutions, from scan to diagnosis. For more information, please
visit www.nanox.vision.
Forward-Looking
Statements:
This
press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical
facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, those relating
to the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization
activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent
acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking
statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,”
“continue,” “anticipate,” “intend,” “should,” “plan,” “should,”
“could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar
expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s
good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance
or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual
results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to continue to develop
of the Nanox imaging system; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial
applications; (iii) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory
clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance
with applicable quality standards and regulatory requirements; (iv) Nanox’s ability to realize the anticipated benefits of acquisitions,
which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage
growth profitably and retain their key employees; (v) Nanox’s ability to enter into and maintain commercially reasonable arrangements
with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vi) the market acceptance of the Nanox imaging system and
the proposed pay-per-scan business model; (vii) Nanox’s expectations regarding collaborations with third-parties and their potential
benefits; and (viii) Nanox’s ability to conduct business globally; (ix) changes in global, political, economic, business, competitive,
market and regulatory forces, including the continuation and escalation of the military conflicts in Israel and current war between
Israel and Hamas; (x) the costs incurred with respect to and the outcome of litigation Nanox is currently subject to and any similar
or other claims and potential litigation it may be subject to in the future; and (xi) risks related to business interruptions resulting
from the COVID-19 pandemic or similar public health crises, among other things.
For
a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to
differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual
Report on Form 20-F for the year ended December 31, 2023, and subsequent filings with the U.S. Securities and Exchange Commission. The
reader should not place undue reliance on any forward-looking statements included in this press release.
Except
as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release
to conform these statements to actual results or to changes in the Company’s expectations.
Non-GAAP
Financial Measures
This
press release includes information about certain financial measures that are not prepared in accordance with generally accepted accounting
principles in the United States (“GAAP”), including non-GAAP net loss attributable to ordinary shares, non-GAAP cost of revenue,
non-GAAP gross profit, non-GAAP gross profit margin, non-GAAP research and development expenses, non-GAAP sales and marketing expenses,
non-GAAP general and administrative expenses and non-GAAP basic and diluted loss per share. These non-GAAP measures are not based on
any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies.
These non-GAAP measures are adjusted for (as applicable) amortization of intangible assets, share-based compensation expenses, change
in contingent earnout liability and legal fees in connection with class-action litigation and the SEC investigation. The Company’s
management and board of directors utilize these non-GAAP financial measures to evaluate the Company’s performance. The Company
provides these non-GAAP measures of the Company’s performance to investors because management believes that these non-GAAP financial
measures, when viewed with the Company’s results under GAAP and the accompanying reconciliations, are useful in identifying underlying
trends in ongoing operations. However, these non-GAAP measures are not measures of financial performance under GAAP and, accordingly,
should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, these non-GAAP measures should
not be considered measures of the Company’s liquidity. A reconciliation of certain GAAP to non-GAAP financial measures has been
provided in the tables included in this press release.
NANO-X
IMAGING LTD.
UNAUDITED
CONDENSED CONSOLIDATED BALANCE SHEETS
(U.S.
dollars in thousands except share and per share data)
| | |
June 30,
2024 | | |
December 31,
2023 | |
| | |
U.S.
Dollars in thousands | |
| Assets | |
| | |
| |
| CURRENT
ASSETS: | |
| | |
| |
| Cash
and cash equivalents | |
| 38,982 | | |
| 56,377 | |
| Restricted
deposit | |
| 45 | | |
| 46 | |
| Marketable
securities | |
| 24,884 | | |
| 26,006 | |
| Accounts
receivables net of allowance for credit losses of $55 as of June 30, 2024 and December 31, 2023, respectively. | |
| 1,508 | | |
| 1,484 | |
| Inventories | |
| 957 | | |
| 2,356 | |
| Prepaid
expenses | |
| 552 | | |
| 1,274 | |
| Other
current assets | |
| 2,698 | | |
| 1,092 | |
| TOTAL
CURRENT ASSETS | |
| 69,626 | | |
| 88,635 | |
| | |
| | | |
| | |
| NON-CURRENT
ASSETS: | |
| | | |
| | |
| Restricted
deposit | |
| 323 | | |
| 327 | |
| Property
and equipment, net | |
| 44,397 | | |
| 42,343 | |
| Operating
lease right-of-use asset | |
| 4,169 | | |
| 4,573 | |
| Intangible
assets | |
| 75,301 | | |
| 80,607 | |
| Other
non-current assets | |
| 1,905 | | |
| 2,163 | |
| TOTAL
NON-CURRENT ASSETS | |
| 126,095 | | |
| 130,013 | |
| TOTAL
ASSETS | |
| 195,721 | | |
| 218,648 | |
| | |
| | | |
| | |
| Liabilities and Shareholders’
Equity | |
| | | |
| | |
| CURRENT
LIABILITIES: | |
| | | |
| | |
| Current
maturities of long-term loan | |
| 3,233 | | |
| 3,490 | |
| Accounts
payable | |
| 1,570 | | |
| 3,303 | |
| Accrued
expenses | |
| 3,638 | | |
| 3,920 | |
| Deferred
revenue | |
| 539 | | |
| 543 | |
| Current
maturities of operating lease liabilities | |
| 804 | | |
| 861 | |
| Other
current liabilities | |
| 3,714 | | |
| 3,407 | |
| TOTAL
CURRENT LIABILITIES | |
| 13,498 | | |
| 15,524 | |
| | |
| | | |
| | |
| NON-CURRENT
LIABILITIES: | |
| | | |
| | |
| Non-current
operating lease liabilities | |
| 3,681 | | |
| 4,045 | |
| Deferred
tax liability | |
| 2,765 | | |
| 2,953 | |
| Other
long-term liabilities | |
| 642 | | |
| 612 | |
| TOTAL
NON-CURRENT LIABILITIES | |
| 7,088 | | |
| 7,610 | |
| TOTAL
LIABILITIES | |
| 20,586 | | |
| 23,134 | |
| | |
| | | |
| | |
| COMMITMENTS
AND CONTINGENCIES (Note 3) | |
| | | |
| | |
| | |
| | | |
| | |
| SHAREHOLDERS’
EQUITY: | |
| | | |
| | |
| Ordinary Shares,
par value NIS 0.01 per share 100,000,000 authorized at June 30, 2024 and December 31 2023,58,497,123 and 57,778,628 issued and outstanding
at June 30, 2024 and December 31, 2023, respectively | |
| 167 | | |
| 165 | |
| Additional
paid-in capital | |
| 521,069 | | |
| 515,887 | |
| Accumulated
other comprehensive loss | |
| (52 | ) | |
| (305 | ) |
| Accumulated
deficit | |
| (346,049 | ) | |
| (320,233 | ) |
| TOTAL
SHAREHOLDERS’ EQUITY | |
| 175,135 | | |
| 195,514 | |
| TOTAL
LIABILITIES AND SHAREHOLDERS’ EQUITY | |
| 195,721 | | |
| 218,648 | |
The
accompanying notes are an integral part of the unaudited condensed consolidated financial statements
NANO-X
IMAGING LTD.
UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE
LOSS
(U.S.
dollars in thousands except share and per share data)
| | |
Six Months Ended
June 30, | | |
Three Months Ended
June 30, | |
| | |
2024 | | |
2023 | | |
2024 | | |
2023 | |
| REVENUE | |
| 5,252 | | |
| 5,029 | | |
| 2,699 | | |
| 2,582 | |
| | |
| | | |
| | | |
| | | |
| | |
| COST
OF REVENUE | |
| 10,159 | | |
| 8,243 | | |
| 5,552 | | |
| 4,273 | |
| | |
| | | |
| | | |
| | | |
| | |
| GROSS
LOSS | |
| (4,907 | ) | |
| (3,214 | ) | |
| (2,853 | ) | |
| (1,691 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| OPERATING
EXPENSES: | |
| | | |
| | | |
| | | |
| | |
| Research
and development, net | |
| 10,032 | | |
| 13,199 | | |
| 4,812 | | |
| 6,913 | |
| Sales
and marketing | |
| 1,634 | | |
| 1,988 | | |
| 834 | | |
| 835 | |
| General
and administrative | |
| 10,958 | | |
| 15,434 | | |
| 5,916 | | |
| 7,626 | |
| Change
in contingent earnout liability | |
| - | | |
| (4,523 | ) | |
| - | | |
| 137 | |
| Other
expenses, net | |
| 101 | | |
| 597 | | |
| 92 | | |
| 629 | |
| TOTAL
OPERATING EXPENSES | |
| 22,725 | | |
| 26,695 | | |
| 11,654 | | |
| 16,140 | |
| OPERATING
LOSS | |
| (27,632 | ) | |
| (29,909 | ) | |
| (14,507 | ) | |
| (17,831 | ) |
| REALIZED
LOSS FROM SALE OF MARKETABLE SECURITIES | |
| - | | |
| (178 | ) | |
| - | | |
| - | |
| FINANCIAL
INCOME, net | |
| 1,646 | | |
| 781 | | |
| 856 | | |
| 380 | |
| OPERATING
LOSS BEFORE INCOME TAXES | |
| (25,986 | ) | |
| (29,306 | ) | |
| (13,651 | ) | |
| (17,451 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| INCOME
TAX BENEFIT | |
| 170 | | |
| 181 | | |
| 76 | | |
| 87 | |
| NET
LOSS | |
| (25,816 | ) | |
| (29,125 | ) | |
| (13,575 | ) | |
| (17,364 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| BASIC
AND DILUTED LOSS PER SHARE | |
| (0.45 | ) | |
| (0.53 | ) | |
| (0.23 | ) | |
| (0.31 | ) |
| Weighted
average number of basic and diluted ordinary shares outstanding (in thousands) | |
| 57,953 | | |
| 55,267 | | |
| 58,005 | | |
| 55,375 | |
| Comprehensive
Loss: | |
| | | |
| | | |
| | | |
| | |
| Net Loss | |
| (25,816 | ) | |
| (29,125 | ) | |
| (13,575 | ) | |
| (17,364 | ) |
| Other
comprehensive loss: | |
| | | |
| | | |
| | | |
| | |
| | |
| | | |
| | | |
| | | |
| | |
| Reclassification
of net losses realized in income statement | |
| - | | |
| 178 | | |
| - | | |
| - | |
| Unrealized
gain from available for-sale securities | |
| 253 | | |
| 783 | | |
| 66 | | |
| 369 | |
| Total
comprehensive loss | |
| (25,563 | ) | |
| (28,164 | ) | |
| (13,509 | ) | |
| (16,995 | ) |
The
accompanying notes are an integral part of the unaudited condensed consolidated financial statements
NANO-X
IMAGING LTD.
UNAUDITED
CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
(U.S.
dollars in thousands, except share and per share data)
| | |
Ordinary
shares | | |
Additional | | |
Accumulated
other | | |
| | |
| |
| | |
Number of
shares | | |
Amount | | |
paid-in
capital | | |
comprehensive
loss | | |
Accumulated
deficit | | |
Total | |
| BALANCE
AT JANUARY 1, 2024 | |
| 57,778,628 | | |
| 165 | | |
| 515,887 | | |
| (305 | ) | |
| (320,233 | ) | |
| 195,514 | |
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Changes
during the period: | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Issuance of ordinary
shares upon exercise of options | |
| 718,495 | | |
| 2 | | |
| 1,604 | | |
| - | | |
| - | | |
| 1,606 | |
| Share-based
compensation | |
| - | | |
| - | | |
| 3,578 | | |
| - | | |
| - | | |
| 3,578 | |
| Unrealized
gain from marketable securities | |
| - | | |
| - | | |
| - | | |
| 253 | | |
| - | | |
| 253 | |
| Net
loss for the period | |
| - | | |
| - | | |
| - | | |
| - | | |
| (25,816 | ) | |
| (25,816 | ) |
| BALANCE
AT JUNE 30, 2024 | |
| 58,497,123 | | |
| 167 | | |
| 521,069 | | |
| (52 | ) | |
| (346,049 | ) | |
| 175,135 | |
| | |
| | |
| | |
Accumulated | | |
| | |
| |
| | |
Ordinary
shares | | |
Additional | | |
other | | |
| | |
| |
| | |
Number of | | |
| | |
paid-in | | |
comprehensive | | |
Accumulated | | |
| |
| | |
shares | | |
Amount | | |
capital | | |
deficit | | |
deficit | | |
Total | |
| | |
U.S. Dollars
in thousands | |
| BALANCE
AT JANUARY 1, 2023 | |
| 55,094,237 | | |
| 158 | | |
| 477,953 | | |
| (1,974 | ) | |
| (259,457 | ) | |
| 216,680 | |
| Changes
during the period: | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Issuance of ordinary
shares upon exercise of options | |
| 210,138 | | |
| * | | |
| 595 | | |
| - | | |
| - | | |
| 595 | |
| Issuance
of ordinary shares under settlement agreement with former shareholders of USARAD Holding Inc. | |
| 255,392 | | |
| 1 | | |
| 1,560 | | |
| - | | |
| - | | |
| 1,561 | |
| Other
comprehensive gain | |
| - | | |
| - | | |
| - | | |
| 961 | | |
| - | | |
| 961 | |
| Share-based
compensation | |
| - | | |
| - | | |
| 2,863 | | |
| - | | |
| - | | |
| 2,863 | |
| Net
loss for the period | |
| - | | |
| - | | |
| - | | |
| - | | |
| (29,125 | ) | |
| (29,125 | ) |
| BALANCE
AT JUNE 30, 2023 | |
| 55,559,767 | | |
| 159 | | |
| 482,971 | | |
| (1,013 | ) | |
| (288,582 | ) | |
| 193,535 | |
| | |
| | |
| | |
Accumulated | | |
| | |
| |
| | |
Ordinary
shares | | |
Additional | | |
other | | |
| | |
| |
| | |
Number of | | |
| | |
paid-in | | |
comprehensive | | |
Accumulated | | |
| |
| | |
shares | | |
Amount | | |
capital | | |
deficit | | |
deficit | | |
Total | |
| | |
U.S. Dollars
in thousands | |
| BALANCE
AT APRIL 1, 2024 | |
| 57,779,033 | | |
| 165 | | |
| 517,388 | | |
| (118 | ) | |
| (332,474 | ) | |
| 184,961 | |
| Changes
during the period: | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Issuance of ordinary
shares upon exercise of options | |
| 718,090 | | |
| 2 | | |
| 1,580 | | |
| - | | |
| - | | |
| 1,582 | |
| Other
comprehensive gain | |
| - | | |
| - | | |
| | | |
| 66 | | |
| - | | |
| 66 | |
| Share-based
compensation | |
| - | | |
| - | | |
| 2,101 | | |
| - | | |
| - | | |
| 2,101 | |
| Net
loss for the period | |
| - | | |
| - | | |
| | | |
| - | | |
| (13,575 | ) | |
| (13,575 | ) |
| BALANCE
AT JUNE 30, 2024 | |
| 58,497,123 | | |
| 167 | | |
| 521,069 | | |
| (52 | ) | |
| (346,049 | ) | |
| 175,135 | |
| | |
| | |
| | |
Accumulated | | |
| | |
| |
| | |
Ordinary
shares | | |
Additional | | |
other | | |
| | |
| |
| | |
Number of | | |
| | |
paid-in | | |
comprehensive | | |
Accumulated | | |
| |
| | |
shares | | |
Amount | | |
capital | | |
deficit | | |
deficit | | |
Total | |
| | |
U.S. Dollars
in thousands | |
| BALANCE
AT APRIL 1, 2023 | |
| 55,150,345 | | |
| 158 | | |
| 479,172 | | |
| (1,382 | ) | |
| (271,218 | ) | |
| 206,730 | |
| Changes
during the period: | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| Issuance of ordinary
shares upon exercise of options | |
| 154,030 | | |
| * | | |
| 419 | | |
| - | | |
| - | | |
| 419 | |
| Issuance
of ordinary shares under settlement agreement with former shareholders of USARAD Holding Inc. | |
| 255,392 | | |
| 1 | | |
| 1,560 | | |
| - | | |
| - | | |
| 1,561 | |
| Other
comprehensive gain | |
| - | | |
| - | | |
| - | | |
| 369 | | |
| - | | |
| 369 | |
| Share-based
compensation | |
| - | | |
| - | | |
| 1,820 | | |
| - | | |
| - | | |
| 1,820 | |
| Net
loss for the period | |
| - | | |
| - | | |
| - | | |
| - | | |
| (17,364 | ) | |
| (17,364 | ) |
| BALANCE
AT JUNE 30, 2023 | |
| 55,559,767 | | |
| 159 | | |
| 482,971 | | |
| (1,013 | ) | |
| (288,582 | ) | |
| 193,535 | |
The
accompanying notes are an integral part of the unaudited condensed consolidated financial statements
NANO-X
IMAGING LTD.
UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(U.S.
dollars in thousands)
| | |
Six
Months Ended
June 30, | |
| | |
2024 | | |
2023 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | |
| | |
| |
| Net
loss for the period | |
| (25,816 | ) | |
| (29,125 | ) |
| Adjustments
required to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
| Share-based
compensation | |
| 3,578 | | |
| 2,863 | |
| Amortization
of intangible assets | |
| 5,306 | | |
| 5,306 | |
| Exchange
rate differentials | |
| (295 | ) | |
| (78 | ) |
| Change
in contingent earnout liability | |
| - | | |
| (4,523 | ) |
| Depreciation | |
| 561 | | |
| 509 | |
| Deferred
tax liability, net | |
| (188 | ) | |
| (188 | ) |
| Realized
loss from sale of marketable securities | |
| - | | |
| 178 | |
| Amortization
of premium, discount and accrued interest on marketable securities | |
| (76 | ) | |
| 527 | |
| Impairment
of property and equipment | |
| 171 | | |
| 145 | |
| Changes
in Operating Assets and Liabilities: | |
| | | |
| | |
| Accounts
receivable | |
| (24 | ) | |
| (454 | ) |
| Inventories | |
| (316 | ) | |
| - | |
| Prepaid
expenses and other current assets | |
| 677 | | |
| 2,236 | |
| Other
non-current assets | |
| 183 | | |
| 98 | |
| Accounts
payable | |
| (1,733 | ) | |
| 957 | |
| Operating
lease assets and liabilities | |
| (17 | ) | |
| (10 | ) |
| Accrued
expenses and other liabilities | |
| 25 | | |
| 692 | |
| Deferred
Revenue | |
| (4 | ) | |
| 4 | |
| Other
long-term liabilities | |
| 30 | | |
| 75 | |
| Net
cash used in operating activities | |
| (17,938 | ) | |
| (20,788 | ) |
| | |
| | | |
| | |
| CASH
FLOWS PROVIDED BY INVESTING ACTIVITIES: | |
| | | |
| | |
| Purchase
of property and equipment | |
| (996 | ) | |
| (1,839 | ) |
| Purchase
of marketable securities | |
| (19,794 | ) | |
| - | |
| Proceeds
from maturity of marketable securities | |
| 21,245 | | |
| 25,507 | |
| Proceeds
from sale of marketable securities | |
| - | | |
| 822 | |
| Net
cash provided by investing activities | |
| 455 | | |
| 24,490 | |
| | |
| | | |
| | |
| CASH
FLOWS FROM FINANCING ACTIVITIES: | |
| | | |
| | |
| | |
| | | |
| | |
| Payment
due to settlement of contingent earnout liabilities | |
| - | | |
| (790 | ) |
| Proceeds
from issuance of ordinary shares upon exercise of options | |
| 45 | | |
| 595 | |
| Net
cash provided by/(used in) financing activities | |
| 45 | | |
| (195 | ) |
| EFFECT
OF CHANGES IN EXCHANGE RATES ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH EQUIVALENTS | |
| 43 | | |
| 25 | |
| NET
CHANGE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH EQUIVALENTS | |
| (17,395 | ) | |
| 3,532 | |
| CASH
AND CASH EQUIVALENTS AND RESTRICTED CASH EQUIVALENTS AT BEGINNING OF THE PERIOD | |
| 56,377 | | |
| 38,529 | |
| CASH
AND CASH EQUIVALENTS AND RESTRICTED CASH EQUIVALENTS AT END OF THE PERIOD | |
| 38,982 | | |
| 42,061 | |
| | |
| | | |
| | |
| SUPPLEMENTARY
INFORMATION ON ACTIVITIES INVOLVING CASH FLOWS | |
| | | |
| | |
| Cash
paid for interest | |
| 71 | | |
| 74 | |
| Cash
paid for income taxes | |
| 51 | | |
| 7 | |
| SUPPLEMENTARY
INFORMATION ON ACTIVITIES NOT INVOLVING CASH FLOWS - | |
| | | |
| | |
| Issuance
of ordinary shares upon exercise of options | |
| 1,561 | | |
| - | |
| Ordinary
shares issued in connection with earnout liability | |
| - | | |
| 1,561 | |
| Operating
lease liabilities arising from obtaining operating right-of use assets | |
| - | | |
| 601 | |
| RECONCILIATION
OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH EQUIVALENTS: |
|
|
|
|
|
|
|
|
| Cash and
cash equivalents |
|
|
38,982 |
|
|
|
41,998 |
|
| Restricted
cash equivalents |
|
|
- |
|
|
|
63 |
|
| Total
cash, cash equivalents and restricted cash equivalents |
|
|
38,982 |
|
|
|
42,061 |
|
The
accompanying notes are an integral part of the unaudited condensed consolidated financial statements
NANO-X
IMAGING LTD.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S.
dollars in thousands, except share and per share data)
NOTE
1 – ORGANIZATION AND DESCRIPTION OF BUSINESS
| |
a. |
The
Company, together with its subsidiaries, develops a commercial-grade tomographic imaging device with a digital X-ray source, provides
teleradiology services and develops artificial intelligence applications designed to be used in real-world medical imaging applications.
The Company’s solution, referred to as the Nanox Multi Source System, has two integrated components – “Nanox.ARC”
and “Nanox.CLOUD”. Nanox.ARC is a medical tomographic imaging system incorporating the Company’s novel digital
X-ray source. Nanox.CLOUD is a platform which employs a matching engine to match medical images to radiologists, provides image repository,
connectivity to diagnostic assistive AI systems, billing and reporting. On April 1, 2021, the Company received clearance from the
FDA to market the Company’s Nanox Cart X-Ray System. On April 28, 2023, the Company received clearance from the FDA to market
the Company’s multi-source Nanox.ARC system. |
The
Company has experienced net losses and negative cash flows from operations since its inception. The Company anticipates such losses will
continue until its product candidates reach commercial profitability.
Based
on the Company’s activities during the period ended June 30, 2024, the Company has sufficient funds for its plans for the next
twelve months from the issuance of these financial statements.
| b. | The
security situation in Israel |
In
October 2023, Israel was attacked by a terrorist organization and entered a state of war. As of the date of issuance of these consolidated
financial statements, the war in Israel is ongoing and continues to evolve. The Company’s headquarters and several manufacturing
and research and development, net facilities are located in Israel. Currently, such activities in Israel remain largely unaffected. The
Company continues to maintain contingency plans with backup manufacturing and assembly locations for key products and components. As
of June 30, 2024, the impact of this war on the Company’s results of operations and financial condition was immaterial, but such
impact may increase, which could be material, as a result of the continuation, escalation, or expansion of such war.
NANO-X
IMAGING LTD.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S.
dollars in thousands, except share and per share data)
NOTE
2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION
The
unaudited consolidated financial statements include the accounts of the Company and its subsidiaries, prepared in accordance with accounting
principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities
and Exchange Commission (“SEC”) for interim financial statements. Accordingly, they do not contain all information
and notes required by U.S. GAAP for annual financial statements. In the opinion of management, these unaudited condensed consolidated
financial statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company’s
condensed consolidated financial position as of June 30, 2024, the condensed consolidated statements of operations and comprehensive
loss for the three and six months ended June 30, 2024 and 2023 and the condensed consolidated
statements of cash flows and the condensed consolidated statements of equity for the six months ended June 30, 2024 and 2023.
The preparation of financial statements in conformity with GAAP requires the Company to make certain estimates and assumptions for
the reporting periods covered by the financial statements. These estimates and assumptions affect the reported amounts of assets, liabilities,
revenues, and expenses. Actual amounts could differ from these estimates.
The
accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements
and notes thereto included in the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2023, filed with
the SEC on April 22, 2024 (the “Annual Report”). For further information, reference is made to the consolidated financial
statements and footnotes thereto included in the Annual Report.
Fair
Value of Financial Instruments
Fair
value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly
transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements,
the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three
broad levels, which are described as follows:
| Level 1: |
Quoted prices (unadjusted)
in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest
priority to Level 1 inputs. |
| |
|
| Level 2: |
Observable prices that
are based on inputs not quoted on active markets, but corroborated by market data. |
| |
|
| Level 3: |
Unobservable inputs are
used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. |
In
determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of
unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.
NANO-X
IMAGING LTD.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S.
dollars in thousands, except share and per share data)
The
Company’s financial instruments consist mainly of cash and cash equivalents, restricted deposit, accounts receivable, marketable
securities, current maturities of long term loan accounts payable, accrued expenses and other liabilities. The fair value of these financial
instruments approximates their carrying value.
| | |
Balance
as of June 30, 2024 | |
| | |
Level
1 | | |
Level
2 | | |
Level
3 | | |
Total | |
| Assets: | |
| | |
| | |
| | |
| |
| Money
market funds (*) | |
| - | | |
| 12,332 | | |
| - | | |
| 12,332 | |
| Marketable
securities (**) | |
| - | | |
| 24,884 | | |
| - | | |
| 24,884 | |
| Total
assets | |
| - | | |
| 37,216 | | |
| - | | |
| 37,216 | |
| | |
| | | |
| | | |
| | | |
| | |
| Liabilities: | |
| | | |
| | | |
| | | |
| | |
| Current
maturities of long term loan | |
| - | | |
| - | | |
| 3,233 | | |
| 3,233 | |
| Total
liabilities | |
| - | | |
| - | | |
| 3,233 | | |
| 3,233 | |
The
Company classifies available-for-sale securities within Level 2 because it uses alternative pricing sources and models utilizing market
observable inputs to determine their fair value.
| | |
Balance
as of December 31, 2023 | |
| | |
Level
1 | | |
Level
2 | | |
Level
3 | | |
Total | |
| Assets: | |
| | |
| | |
| | |
| |
| Money
market funds (*) | |
| - | | |
| 28,373 | | |
| | | |
| 28,373 | |
| Marketable
securities (**) | |
| - | | |
| 26,006 | | |
| - | | |
| 26,006 | |
| Total
assets | |
| - | | |
| 54,379 | | |
| - | | |
| 54,379 | |
| | |
| | | |
| | | |
| | | |
| | |
| Liabilities: | |
| | | |
| | | |
| | | |
| | |
| Current
maturities of Long term loan | |
| - | | |
| - | | |
| 3,378 | | |
| 3,378 | |
| Total
liabilities | |
| - | | |
| - | | |
| 3,378 | | |
| 3,378 | |
NANO-X
IMAGING LTD.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S.
dollars in thousands, except share and per share data)
| (*) |
As of June
30, 2024, approximately $12,332 thousand of Money market funds were classified under “Cash and Cash equivalents”
in the consolidated balance sheets as such securities met all applicable classification criteria. As of December 31, 2023, approximately
$28,373 thousand of Money market funds were classified under “Cash and Cash equivalents” in the consolidated balance
sheets as such securities met all applicable classification criteria. |
| (**) |
The
following tables summarize the amortized cost, unrealized gains and losses, and fair value of available-for-sale marketable securities
as of June 30, 2024 and December 31, 2023: |
| | |
June
30, 2024 | |
| | |
Fair
value | | |
Cost
or
amortized
cost | | |
Gross
unrealized
holding
loss | |
| Level 2 securities: | |
| | |
| | |
| |
| Municipal
bonds | |
| 1,256 | | |
| 1,256 | | |
| - | |
| Corporate
debt | |
| 14,714 | | |
| 14,763 | | |
| (49 | ) |
| Certificates of
deposit | |
| 1,995 | | |
| 1,995 | | |
| - | |
| Other | |
| 6,919 | | |
| 6,922 | | |
| (3 | ) |
| Total | |
| 24,884 | | |
| 24,936 | | |
| (52 | ) |
| | |
December
31, 2023 | |
| | |
Fair
value | | |
Cost
or
amortized
cost | | |
Gross
unrealized
holding
loss | |
| Level 2 securities: | |
| | |
| | |
| |
| Municipal
bonds | |
| 2,263 | | |
| 2,291 | | |
| (28 | ) |
| Corporate
debt | |
| 19,441 | | |
| 19,715 | | |
| (274 | ) |
| Certificates of
deposit | |
| 2,989 | | |
| 2,989 | | |
| - | |
| Other | |
| 1,313 | | |
| 1,316 | | |
| (3 | ) |
| Total | |
| 26,006 | | |
| 26,311 | | |
| (305 | ) |
As
of June 30, 2024 and December 31, 2023, the Company’s debt securities and certificates of deposit had the following maturity dates:
| | |
June
30,
2024 | | |
December 31,
2023 | |
| Due
within one year | |
| 24,884 | | |
| 26,006 | |
| | |
| | | |
| | |
| Total | |
| 24,884 | | |
| 26,006 | |
| New Accounting Pronouncements |
New accounting
pronouncements effective in future periods:
Improvements
to Reportable Segments Disclosures
In November
2023, the FASB issued ASU 2023-07 “Segment Reporting–Improvements to Reportable Segments Disclosures (Topic 280)”
to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The
amendments in this ASU (1) require that a public entity disclose, on an annual and interim basis, significant segment expenses that are
regularly provided to the chief operating decision maker (“CODM”) and included within each reported measure of segment profit
or loss; (2) require that a public entity disclose, on an annual and interim basis, an amount for other segment items by reportable segment
and a description of its composition; (3) require that a public entity provide all annual disclosures about a reportable segment’s
profit or loss and assets currently required by Topic 280 in interim periods; (4) clarify that if the CODM uses more than one measure
of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources, a public entity may report one or
more of those additional measures; and (5) require that a public entity disclose the title and position of the CODM and an explanation
of how the CODM uses the reported measure or measures of segment profit or loss in assessing segment performance and deciding how to
allocate resources. The amendments in this ASU are effective for fiscal years beginning after December 15, 2023, and interim
periods within fiscal years beginning after December 15, 2024, and should be applied retrospectively to all periods presented.
Early adoption is permitted. The Company is currently evaluating the impact of the adoption of these amendments on its consolidated financial
statements.
Improvements
to Income Tax Disclosures
In December
2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740)–Improvements to Income Tax Disclosures”
to enhance the transparency and decision usefulness of income tax disclosures, primarily related to the rate reconciliation and income
taxes paid information. The amendments in this ASU require that public entities, on an annual basis, disclose specific categories in
the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. This ASU also requires
that all entities disclose, on an annual basis, (1) the amount of income taxes paid disaggregated by federal, state, and foreign taxes,
(2) the amount of income taxes paid disaggregated by individual jurisdictions in which income taxes paid is equal to or greater than five percent
of total income taxes paid, (3) income or loss from continuing operations before income tax expense or benefit disaggregated between
domestic and foreign, and (4) income tax expense or benefit from continuing operations disaggregated by federal, state, and foreign.
For the Company, the amendments in this “ASU are effective for annual periods beginning after December 15, 2025, and
should be applied on a prospective basis with the option to apply retrospectively. Early adoption is permitted for annual financial statements
that have not yet been issued or made available for issuance. The Company is currently evaluating the impact of the adoption
of these amendments on its consolidated financial statements.
NANO-X
IMAGING LTD.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S.
dollars in thousands, except share and per share data)
NOTE
3 - COMMITMENTS AND CONTINGENCIES:
From
time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business.
However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time
that may harm the Company’s business.
In
September 2020, two securities class action complaints were filed in the United States District Court for the Eastern District of New
York against the Company and certain then-current officers and a director, which were subsequently consolidated and captioned as White
v. Nano-X Imaging Ltd. et al., Case No. 1:20-cv-04355 (the “White Action”), alleging violations of securities laws on behalf
of all persons and entities that purchased or otherwise acquired the Company’s publicly traded securities between August 21, 2020
and September 15, 2020, and seeking unspecified damages. In addition, on October 5, 2021, a class action complaint was filed in the United
States District Court for the Eastern District of New York against the Company and certain of its officers, captioned McLaughlin v. Nano-X
Imaging Ltd. et al., Case No. 1:21-cv-05517 (the “McLaughlin Action”). The amended complaint in that action, filed on April
12, 2022, alleges that defendants violated the federal securities laws in connection with certain disclosures concerning the cost of
the Nanox.ARC system as well as the comparison of the Nanox.ARC to CT scanners, among other allegations. The Lead Plaintiff in the McLaughlin
Action seeks to represent a class of investors who purchased the Company’s publicly-traded securities between August 21, 2020 and
November 17, 2021. The Company entered into a term sheet on April 28, 2023, to settle all shareholder class action litigation related
to the McLaughlin Action and the consolidated White Action. On June 2, 2023, the Company entered into a formal settlement agreement to
settle the McLaughlin Action and the consolidated White Action for $8 million. On October 31, 2023, Magistrate Judge Kuo preliminarily
approved the settlement. Due to the settlement agreement, during December 2023 the Company deposited $5 million and the D&O insurance
carrier deposited $3 million (The $3 million was recorded as other income in the consolidated statements of operations and comprehensive
loss for the year ended December 31, 2023) in a trust account in connection with the settlement agreement. Therefore, as of December
31, 2023, the Company had no accrual in connection with the settlement agreement. On February 15, 2024, the court held a final approval
hearing, during which she requested that the parties submit updated settlement claims information by letter on or before February 29,
2024 for incorporation into a final report and recommendation. The parties submitted the letter on February 29, 2024, and on April 17,
2024, Magistrate Judge Kuo issued a report and recommendation recommending that Judge Kovner grant the motion for final approval of the
settlement. On May 7, 2024, Judge Kovner entered an order adopting Magistrate Judge Kuo’s report and recommendation and finally
approving the settlement. On May 10, 2024, the judgment was entered, and the case was dismissed with prejudice.
On
May 1, 2023, the Company received a notice alleging several causes of action, including breach of a consulting agreement between the
claimant and Nanox Imaging PLC (the “Gibraltar Entity”) that was entered into in 2015. The claimant’s demand from the
Company is for the payment of approximately $1.26 million for unpaid consulting fees from the Gibraltar Entity and approximately $25
million connection with his claimed entitlement to securities in the Gibraltar Entity. On or about December 21, 2023, a claim was
filed in Israel against the Company, the Gibraltar Entity and the late Mr. Ran Poliakine, based on allegations previously dismissed by
a U.S. court In the State of California. The Company reiterates its strong denial of the plaintiff’s baseless claims and emphasizes
that the Company was never a party to the consulting agreement with the plaintiff. In addition, the Company is not responsible for any
potential liabilities of the Gibraltar Entity, which is a separate legal entity. The Company is currently reviewing and analyzing the
claim filed in Israel and will take all necessary steps to vigorously defend itself against these unfounded allegations. The Company
remains confident in its legal position and is committed to protecting its shareholders and stakeholders. On April 5, 2024, the Gibraltar
Entity filed an amended claim and a request for an anti-suit injunction (“ASI”) in Gibraltar against the plaintiff. A hearing
for the ASI request has been scheduled for September 25, 2024.
The
Company has not yet responded to the Claim and will submit a statement of defense by September 14, 2024.
Under
the Innovation Law (formerly known as the Encouragement of Industrial Research and Development Law, 5744-1984) as currently in effect,
Nanox AI is required to pay royalties to the Israel Innovation Authority (the “IIA”) of 3% on sales of products and services
based on technology and know-how developed using such IIA research and development grants, until 100% (which may be increased under certain
circumstances) of the grant, linked to the U.S. dollar and bearing interest at the SOFR rate, is repaid. As of June 30, 2024, Nanox AI
had paid royalties to the IIA in the amount of approximately $56 and had a remaining liability to the IIA of approximately $3.2 million.
NANO-X
IMAGING LTD.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S.
dollars in thousands, except share and per share data)
NOTE
4 - RELATED PARTIES:
Related
party balances at June 30, 2024 and December 31, 2023 consisted of the following:
| | |
June 30,
2024 | | |
December 31,
2023 | |
| | |
(U.S.
Dollars in thousands) | |
| (a)
Due from Illumigyn | |
$ | 17 | | |
$ | 17 | |
| (b)
Due to Wellsense Technologies Ltd. | |
| (14 | ) | |
| (13 | ) |
| (c)
Due from Six-Eye Interactive | |
| 4 | | |
| 4 | |
| Total
from related parties | |
$ | 7 | | |
$ | 8 | |
| (*) | From
2024 Illumigyn is no longer a related party |
NOTE
5 – DEFERRED REVENUE
The
following table represents the changes in deferred revenue for six months ended June 30, 2024:
| | |
Deferred | |
| | |
Revenue | |
| | |
(U.S. Dollars | |
| | |
in thousands) | |
| Balance
at December 31, 2023 (*) | |
$ | 543 | |
| Additions | |
| 147 | |
| Revenue
recognized in the reported period - | |
| (151 | ) |
| Balance
at June 30, 2024 (*) | |
$ | 539 | |
| * |
Includes
only short term deferred revenue in the Company’s consolidated balance sheets as of December 31, 2023 and June 30,2024. |
NANO-X
IMAGING LTD.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S.
dollars in thousands, except share and per share data)
NOTE
6 - SHAREHOLDERS’ EQUITY:
The
following table presents the number of authorized and issued and outstanding shares as of each reporting date for each class of shares:
| | |
June
30, 2024 | | |
December
31, 2023 | |
| | |
Authorized | | |
Issued and
Outstanding | | |
Authorized | | |
Issued and
Outstanding | |
| Ordinary shares | |
| 100,000,000 | | |
| 58,497,123 | | |
| 100,000,000 | | |
| 57,778,628 | |
| Total | |
| 100,000,000 | | |
| 58,497,123 | | |
| 100,000,000 | | |
| 57,778,628 | |
The
Company’s board of directors also approved the Plan for the purpose of selecting the capital gains tax track, under Section 102
of the Israeli Income Tax Ordinance, for options granted to the Company’s Israeli employees. As of June 30, 2024, there were 874,926
ordinary shares reserved for the equity incentive plan.
During
the six months ended June 30, 2024, 718,495 options to purchase ordinary shares were exercised to ordinary shares in consideration of
$1,606. The consideration of $1,561 for 706,290 options to purchase ordinary shares were recorded as other current assets in the Company’s
balance sheet as of June 30, 2024, received at the beginning of July 2024.
Share-based
compensation
During
the six months ended June 30, 2024, the Company granted 203,500 options and 190,000 RSUs to several officers and employees of the Company,
as the following:
| |
a. |
On
March 25, 2024, the Company granted employees of the Company a total of 11,500 options to purchase ordinary shares at an exercise
price of $17.63 per share. The options shall equally vest over a period of 4 years; one quarter of the options vest on the first
anniversary of the vesting commencement date and the rest vest quarterly over the following three years. The options expire on the
tenth anniversary of their grant date. The fair value of options granted was $73 and the underlying data used for computing the fair
value of the options are as follows: |
| | |
March 25,
2024 | |
| Stock price of one ordinary share | |
$ | 9.75 | |
| Dividend yield | |
| 0 | |
| Expected volatility | |
| 82.66 | % |
| Risk-free interest rate | |
| 4.24 | % |
| Expected term (years) | |
| 6.25 | |
NANO-X
IMAGING LTD.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S.
dollars in thousands, except share and per share data)
| |
b. |
On
April 14, 2024, the Company granted employees of the Company a total of 42,000 options to purchase ordinary shares of the Company
at an exercise price of $17.63 per share. The options shall equally vest over a period of 4 years; one quarter of the options vest
on the first anniversary of the vesting commencement date and the rest vest quarterly over the following three years. The options
expire on the tenth anniversary of their grant date. The fair value of options granted was $265 and the underlying data used for
computing the fair value of the options are as follows: |
| | |
April
14,
2024 | |
| Stock price of one ordinary share | |
$ | 9.71 | |
| Dividend yield | |
| 0 | |
| Expected volatility | |
| 82.55 | % |
| Risk-free interest rate | |
| 4.53 | % |
| Expected term (years) | |
| 6.25 | |
| |
c. |
On
June 25, 2024, the Company granted the Chief Executive Officer and active Chairman of the board a total of 150,000 options to purchase
ordinary shares of the Company at an exercise price of $11.52 per share. The options shall equally vest over a period of 4 years.
The options expire on the tenth anniversary of their grant date. The fair value of options granted was $764 and the underlying data
used for computing the fair value of the options are as follows: |
| | |
June
25,
2024 | |
| Stock price of one ordinary share | |
$ | 6.52 | |
| Dividend yield | |
| 0 | |
| Expected volatility | |
| 80.29 | % |
| Risk-free interest rate | |
| 4.23 | % |
| Expected term (years) | |
| 10 | |
| |
d. |
On
April 16, 2024, the Company granted a total of 140,000 RSUs to several officers of the Company. The RSUs shall equally vest over
a period of 6 months. The fair value of RSUs granted was $1,298. On June 25, 2024, the Company granted a total of 50,000 RSUs to
the Chief Executive Officer of the Company. The RSUs shall equally vest over a period of 6 months.. The fair value of RSUs granted
was $326. |
NANO-X
IMAGING LTD.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S.
dollars in thousands, except share and per share data)
NOTE
7 - SEGMENTS OF OPERATIONS
The
Company reports segment information based on the “management” approach. The management approach designates the internal reporting
used by management for making decisions and assessing performance as the source of the Company’s reportable operating segments.
The Company manages its business primarily on a service basis. The Company’s reportable segments consist of the Nanox.ARC division,
the radiology services division and the AI solutions division. Each one is managed separately to better align with the Company’s
customers and distribution partners and the unique market dynamics of each segment. Operating income for each segment includes net sales
to third parties, related cost of sales and operating expenses directly attributable to the segment. Costs excluded from segment operating
income include various corporate expenses such as income taxes. The Company does not include intercompany transfers between segments
for management reporting.
The
accounting policies of the various segments are the same as those described in Note 2, “Summary of Significant Accounting Policies”
in the Annual Report. The Company evaluates the performance of its reportable operating segments based on net sales and operating loss.
| | |
Six
months ended
June 30, 2024
(U.S. dollars in thousands) | |
| | |
Nanox.
ARC | | |
Radiology
Services | | |
AI
Solutions | | |
Total | |
| Revenues | |
$ | 116 | | |
$ | 4,926 | | |
$ | 210 | | |
$ | 5,252 | |
| Segment
operating loss | |
| (21,055 | ) | |
| (875 | ) | |
| (5,702 | ) | |
| (27,632 | ) |
| Financial
income, net | |
| | | |
| | | |
| | | |
| 1,646 | |
| Loss
before taxes on income | |
| (18,968 | ) | |
| (949 | ) | |
| (6,069 | ) | |
$ | (25,986 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Depreciation
and amortization expenses | |
$ | 499 | | |
$ | 1,318 | | |
$ | 4,051 | | |
$ | 5,868 | |
| Stock
based compensation | |
$ | 3,130 | | |
$ | 86 | | |
$ | 362 | | |
$ | 3,578 | |
| Total
Assets | |
$ | 114,380 | | |
$ | 20,714 | | |
$ | 60,627 | | |
$ | 195,721 | |
| | |
Six
months ended
June 30, 2023
(U.S. dollars in thousands) | |
| | |
Nanox.
ARC | | |
Radiology
Services | | |
AI
Solutions | | |
Total | |
| Revenues | |
$ | - | | |
$ | 4,927 | | |
$ | 102 | | |
$ | 5,029 | |
| Segment
operating profit (loss) | |
| (24,877 | ) | |
| 3,964 | | |
| (8,996 | ) | |
| (29,909 | ) |
| Realized
loss from sale of marketable securities | |
| | | |
| | | |
| | | |
| (178 | ) |
| Financial
income | |
| | | |
| | | |
| | | |
| 781 | |
| Profit
(Loss) before taxes on income | |
| (23,989 | ) | |
| 3,935 | | |
| (9,252 | ) | |
$ | (29,306 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Depreciation
and amortization expenses | |
$ | 418 | | |
$ | 1,321 | | |
$ | 4,076 | | |
$ | 5,815 | |
| Change
in obligation in earn-out liabilities | |
$ | - | | |
$ | (4,523 | ) | |
$ | - | | |
$ | (4,523 | ) |
| Stock
based compensation | |
$ | 2,270 | | |
$ | 113 | | |
$ | 480 | | |
$ | 2,863 | |
| Total
Assets | |
$ | 123,279 | | |
$ | 29,734 | | |
$ | 71,872 | | |
$ | 224,885 | |
NANO-X
IMAGING LTD.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
(U.S.
dollars in thousands, except share and per share data)
| | |
Three
months ended
June 30, 2024
(U.S. dollars in thousands) | |
| | |
Nanox.
ARC | | |
Radiology
Services | | |
AI
Solutions | | |
Total | |
| Revenues | |
$ | 68 | | |
$ | 2,518 | | |
$ | 113 | | |
$ | 2,699 | |
| Segment
operating loss | |
| (11,130 | ) | |
| (383 | ) | |
| (2,994 | ) | |
| (14,507 | ) |
| Financial
income, net | |
| | | |
| | | |
| | | |
| 856 | |
| Loss
before taxes on income | |
| (10,038 | ) | |
| (419 | ) | |
| (3,194 | ) | |
$ | (13,651 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Depreciation
and amortization expenses | |
$ | 244 | | |
$ | 659 | | |
$ | 2,026 | | |
$ | 2,929 | |
| Stock
based compensation | |
$ | 1,878 | | |
$ | 43 | | |
$ | 180 | | |
$ | 2,101 | |
| | |
Three
months ended
June 30, 2023
(U.S. dollars in thousands) | |
| | |
Nanox.
ARC | | |
Radiology
Services | | |
AI
Solutions | | |
Total | |
| Revenues | |
| - | | |
| 2,529 | | |
| 53 | | |
| 2,582 | |
| Segment
operating loss | |
$ | (13,211 | ) | |
$ | (483 | ) | |
$ | (4,137 | ) | |
$ | (17,831 | ) |
| Financial
income | |
| | | |
| | | |
| | | |
| 380 | |
| | |
| | | |
| | | |
| | | |
| | |
| Loss
before taxes on income | |
| (12,668 | ) | |
| (497 | ) | |
| (4,286 | ) | |
$ | (17,451 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Depreciation
and amortization expenses | |
$ | 211 | | |
$ | 659 | | |
$ | 2,037 | | |
$ | 2,907 | |
| Change
in obligation in earn-out liabilities | |
$ | - | | |
$ | 137 | | |
$ | - | | |
$ | 137 | |
| Stock
based compensation | |
$ | 1,515 | | |
$ | 57 | | |
$ | 248 | | |
$ | 1,820 | |
For
the six months and three months periods ended June 30, 2024 and June 30, 2023,
the Company’s revenues in the United States constituted approximately 96% and 99% of
the Company’s total revenue, respectively.
NOTE
8 - LOSS PER SHARE:
As
of June 30, 2024 and 2023, the Company had outstanding 4,455,301 warrants and 2,312,443 warrants,
respectively. As of June 30, 2024, and 2023, the Company had 4,470,557 and 5,165,492 outstanding
options awards and 208,326 and 53,826 outstanding RSUs awards, respectively. These warrants
and awards were not considered when calculating diluted loss per share since their effect
is anti-dilutive. In addition, contingently issuable ordinary shares that are issuable based
on certain conditions are not included in the potential dilutive shares in calculating the
diluted loss per share.
UNAUDITED
RECONCILIATION OF GAAP AND NON-GAAP RESULTS
(U.S.
dollars in thousands (except per share data))
Use
of Non-GAAP Financial Measures
The
unaudited condensed consolidated financial information is prepared in conformity with GAAP. The Company uses information about certain
financial measures that are not prepared in accordance with GAAP, including non-GAAP net loss attributable to ordinary shares, non-GAAP
cost of revenue, non-GAAP gross profit, non-GAAP gross profit margin, non-GAAP research and development expenses non-GAAP sales and marketing
expenses, non-GAAP general and administrative expenses, Non-GAAP other expenses (income) and non-GAAP basic and diluted loss per share.
These non-GAAP measures are adjusted for (as applicable) amortization of intangible assets, share-based compensation expenses, change
in contingent earnout liability, expenses related to an offering and legal fees in connection with the class-action litigation and the
SEC investigation. The Company believes that separate analysis and exclusion of the one-off or non-cash impact of the above reconciling
items (as applicable) adds clarity to the constituent parts of its performance. The Company reviews these non-GAAP financial measures
together with GAAP financial measures to obtain a better understanding of its operating performance. It uses the non-GAAP financial measures
for planning, forecasting, and measuring results against the forecast. The Company believes that the non-GAAP financial measures are
useful supplemental information for investors and analysts to assess its operating performance. However, these non-GAAP measures are
not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators
of operating performance.
Reconciliation
of GAAP net loss attributable to ordinary shares to Non-GAAP net loss attributable to ordinary shares and Non-GAAP basic and diluted
loss per share (U.S. dollars in thousands)
| | |
Six Months
Ended | | |
Three Months
Ended | |
| | |
June
30, | | |
June
30, | |
| | |
2024 | | |
2023 | | |
2024 | | |
2023 | |
| GAAP
net loss attributable to ordinary shares | |
| 25,816 | | |
| 29,125 | | |
| 13,575 | | |
| 17,364 | |
| Non-GAAP
adjustments: | |
| | | |
| | | |
| | | |
| | |
| Less:
Class-action litigation and SEC investigation | |
| 76 | | |
| 4,417 | | |
| 44 | | |
| 2,181 | |
| Less:
Amortization of intangible assets | |
| 5,306 | | |
| 5,306 | | |
| 2,653 | | |
| 2,653 | |
| Less:
Offering expenses | |
| 420 | | |
| - | | |
| 420 | | |
| - | |
| Less
(Add): Change in the fair value of earn out liabilities’ obligation | |
| - | | |
| (4,523 | ) | |
| - | | |
| 137 | |
| Less:
accrual in connection with the estimated settlement of the SEC investigation | |
| - | | |
| 650 | | |
| - | | |
| 650 | |
| Less:
Share-based compensation | |
| 3,578 | | |
| 2,863 | | |
| 2,101 | | |
| 1,820 | |
| Non-GAAP
net loss attributable to ordinary shares | |
| 16,436 | | |
| 20,412 | | |
| 8,357 | | |
| 9,923 | |
| BASIC
AND DILUTED LOSS PER SHARE | |
| 0.28 | | |
| 0.37 | | |
| 0.14 | | |
| 0.18 | |
| WEIGHTED
AVERAGE NUMBER OF ORDINARY SHARES (in thousands) | |
| 57,953 | | |
| 55,267 | | |
| 58,005 | | |
| 55,375 | |
Reconciliation
of GAAP cost of revenue to Non-GAAP cost of revenue (U.S. dollars in thousands)
| GAAP
cost of revenue | |
| 10,159 | | |
| 8,243 | | |
| 5,552 | | |
| 4,273 | |
| Non-GAAP
adjustments: | |
| | | |
| | | |
| | | |
| | |
| Amortization
of intangible assets | |
| 5,112 | | |
| 5,112 | | |
| 2,556 | | |
| 2,556 | |
| Share-based
compensation | |
| 112 | | |
| 28 | | |
| 59 | | |
| 14 | |
| Non-GAAP
cost of revenue | |
| 4,935 | | |
| 3,103 | | |
| 2,937 | | |
| 1,703 | |
Reconciliation
of GAAP gross loss to Non-GAAP gross profit (U.S. dollars in thousands)
| GAAP
gross loss | |
| (4,907 | ) | |
| (3,214 | ) | |
| (2,853 | ) | |
| (1,691 | ) |
| Non-GAAP
adjustments: | |
| | | |
| | | |
| | | |
| | |
| Amortization
of intangible assets | |
| 5,112 | | |
| 5,112 | | |
| 2,556 | | |
| 2,556 | |
| Share-based
compensation | |
| 112 | | |
| 28 | | |
| 59 | | |
| 14 | |
| Non-GAAP
gross profit (loss) | |
| 317 | | |
| 1,926 | | |
| (238 | ) | |
| 879 | |
Reconciliation
of GAAP gross loss margin to Non-GAAP gross profit margin (in percentage of revenue)
| GAAP
gross loss margin | |
| (93.43 | )% | |
| (63.91 | )% | |
| (105.71 | )% | |
| (65.49 | )% |
| Non-GAAP
adjustments: | |
| | | |
| | | |
| | | |
| | |
| Amortization
of intangible assets | |
| 97.33 | % | |
| 101.65 | % | |
| 94.7 | % | |
| 98.99 | % |
| Share-based
compensation | |
| 2.13 | % | |
| 0.56 | % | |
| 2.19 | % | |
| 0.54 | % |
| Non-GAAP
gross profit (loss) margin | |
| 6.03 | % | |
| 38.3 | % | |
| (8.82 | )% | |
| 34.04 | % |
Reconciliation
of GAAP research and development, expenses to Non-GAAP research and development expenses, net (U.S. dollars in thousands)
| GAAP
research and development expenses, net | |
| 10,032 | | |
| 13,199 | | |
| 4,812 | | |
| 6,913 | |
| Non-GAAP
adjustments: | |
| | | |
| | | |
| | | |
| | |
| Share-based
compensation | |
| 1,316 | | |
| 1,735 | | |
| 727 | | |
| 947 | |
| Non-GAAP
research and development expenses, net | |
| 8,716 | | |
| 11,464 | | |
| 4,085 | | |
| 5,966 | |
Reconciliation
of GAAP sales and marketing expenses to Non-GAAP sales and marketing expenses (U.S. dollars in thousands)
| GAAP
sales and marketing expenses | |
| 1,634 | | |
| 1,988 | | |
| 834 | | |
| 835 | |
| Non-GAAP
adjustments: | |
| | | |
| | | |
| | | |
| | |
| Amortization
of intangible assets | |
| 194 | | |
| 194 | | |
| 97 | | |
| 97 | |
| Share-based
compensation | |
| 350 | | |
| 185 | | |
| 204 | | |
| 107 | |
| | |
| | | |
| | | |
| | | |
| | |
| Non-GAAP
sales and marketing expenses | |
| 1,090 | | |
| 1,609 | | |
| 533 | | |
| 631 | |
Reconciliation
of GAAP general and administrative expenses to Non-GAAP general and administrative expenses (U.S. dollars in thousands)
| GAAP
general and administrative expenses | |
| 10,958 | | |
| 15,434 | | |
| 5,916 | | |
| 7,626 | |
| Non-GAAP
adjustments: | |
| | | |
| | | |
| | | |
| | |
| Class-action
litigation and SEC investigation | |
| 76 | | |
| 4,417 | | |
| 44 | | |
| 2,181 | |
| Offering
expenses | |
| 420 | | |
| - | | |
| 420 | | |
| - | |
| Share-based
compensation | |
| 1,800 | | |
| 915 | | |
| 1,111 | | |
| 752 | |
| | |
| | | |
| | | |
| | | |
| | |
| Non-GAAP
general and administrative expenses | |
| 8,662 | | |
| 10,102 | | |
| 4,341 | | |
| 4,693 | |
Reconciliation
of GAAP other expenses to Non-GAAP other expenses (income) (U.S. dollars in thousands)
| GAAP
other expenses | |
| 101 | | |
| 597 | | |
| 92 | | |
| 629 | |
| Non-GAAP
adjustments: | |
| | | |
| | | |
| | | |
| | |
| Accrual
in connection with the estimated settlement of the SEC investigation | |
| - | | |
| 650 | | |
| - | | |
| 650 | |
| | |
| | | |
| | | |
| | | |
| | |
| Non-GAAP
other expenses (income) | |
| 101 | | |
| (53 | ) | |
| 92 | | |
| (21 | ) |
Nano X Imaging (NASDAQ:NNOX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Nano X Imaging (NASDAQ:NNOX)
Historical Stock Chart
From Dec 2023 to Dec 2024
